Baseline characteristics of the treatment groups
| Control (n = 25) | Latanoprost (randomised) (n = 25) | Latanoprost (non-randomised) (n = 26) | |
|---|---|---|---|
| Sex | |||
| Male | 14 (56%) | 16 (64%) | 15 (58%) |
| Female | 11 (44%) | 9 (36%) | 11 (42%) |
| Age (years) | |||
| Mean | 71.5 | 65.7 | 74.0 |
| SD | 10.6 | 11.7 | 9.3 |
| Smoking status | |||
| Non-smoker | 14 (56%) | 11 (46%) | 10 (42%) |
| Ex-smoker | 11 (44%) | 8 (33%) | 13 (54%) |
| Current smoker | 0 | 5 (21%) | 1 (4%) |
| Unknown | 0 | 1 | 2 |
| Currently using | |||
| α Blockers | 2 (8%) | 0 | 2 (8%) |
| β Blockers | 3 (12%) | 3 (12%) | 4 (15%) |
| Treated eye | |||
| Left | 13 (52%) | 14 (56%) | 14 (54%) |
| Right | 12 (48%) | 11 (44%) | 12 (46%) |
| Disease duration (months) | |||
| Mean | 12.1 | 12.4 | 13.3 |
| SD | 4.7 | 5.5 | 7.3 |
| Average baseline IOP (mm Hg) | |||
| Mean | 14.4 | 17.5 | 16.4 |
| SD | 2.5 | 1.8 | 2.6 |
| Maximum baseline IOP (mm Hg) | |||
| Mean | 17.6 | 20.8 | 19.6 |
| SD | 3.0 | 2.1 | 2.7 |
| Range of baseline IOP (mm Hg) | |||
| Mean | 6.2 | 6.5 | 6.1 |
| SD | 2.6 | 1.9 | 2.0 |
| Length of treatment (months) | |||
| Mean | NA | 11.0 | 11.6 |
| Median | 9 | 10 | |
| SD | 5.3 | 6.4 | |
| Time until follow up (months) | |||
| Mean | 11.1 | 11.4 | 12.8 |
| SD | 4.2 | 5.4 | 6.3 |
| Central corneal thickness (μm) | |||
| Mean | 532.0 | 521.6 | 522.2 |
| SD | 27.9 | 34.4 | 33.4 |